financial estimates
Novartis Q1 Revenues Grow 1 Percent Amid Organizational Restructuring, Shifting Growth Drivers
The firm highlighted revenue growth for its CDK4/6 inhibitor Kisqali and strong sales potential for recent launches Pluvicto and Scemblix, but not for its cell therapy Kymriah.
Silverback Discontinues Targeted Oncology Programs, Reduces Staff
The company terminated development of two antibody-drug conjugates due to lackluster anti-tumor activity and cytokine-related adverse events.
Exact Sciences Projects up to $475M in Q4 Revenues, Acquires Testing Lab, Inks Licensing Deal
The approximately 2 percent increase over Q4 2020 results beat analysts' expectations, and the acquisition news heralds market expansion into hereditary cancer testing.
Novartis Q3 Revenues Increase 6 Percent Assisted by Oncology Rx Sales Growth
Several precision oncology drugs performed well during the quarter, helping bolster Q3 revenues for the company.
Roche Q2 Pharmaceutical Revenues Increase 4 Percent
Increasing revenues from newer oncology drugs like atezolizumab and strong diagnostics division revenues helped diminish the impact of the pandemic.